Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group

• Published in: Fertility and sterility Vol. 54; no. 3; p. 419
• Main Authors: Dlugi, A M, Miller, J D, Knittle, J
• Format: Journal Article
• Language: English
• Published: United States 01-09-1990
• Subjects: Adult; Antineoplastic Agents - adverse effects; Antineoplastic Agents - standards; Antineoplastic Agents - therapeutic use; Delayed-Action Preparations; Double-Blind Method; Endometriosis - drug therapy; Endometriosis - epidemiology; Endometriosis - pathology; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone - adverse effects; Gonadotropin-Releasing Hormone - analogs & derivatives; Gonadotropin-Releasing Hormone - standards; Gonadotropin-Releasing Hormone - therapeutic use; Humans; Leuprolide; Multicenter Studies as Topic; Pain - drug therapy; Pain - pathology; Randomized Controlled Trials as Topic
• ISSN: 0015-0282

The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients. Dysmenorrhea, pelvic pain, and pelvic tenderness all responded significantly to LA treatment in comparison with placebo. Menses were suppressed in all of the LA patients. Estradiol decreased significantly to menopausal levels in the LA group. There were small to moderate changes in a variety of laboratory parameters, but these were not clinically significant. The most common adverse event was vasodilatation, occurring significantly more frequently in the LA group. Lupron depot was shown to be safe and effective in inducing a hormonal and menstrual suppression in patients with endometriosis, resulting in alleviation of pain symptoms.